Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents

Mohd Hanafiah, 2013, Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology, 57, 1333, 10.1002/hep.26141 Asselah, 2016, Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives, Liver Int, 36, 47, 10.1111/liv.13027 Algahtani, 2015, Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials, Hepatology, 62, 25, 10.1002/hep.27890 Sebastiani, 2014, Chronic hepatitis C and liver fibrosis, World J Gastroenterol, 20, 11033, 10.3748/wjg.v20.i32.11033 Rousselet, 2005, Sources of variability in histological scoring of chronic viral hepatitis, Hepatology, 41, 257, 10.1002/hep.20535 Forns, 2002, Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model, Hepatology, 36, 986, 10.1053/jhep.2002.36128 Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346 2015, EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006 Carrión, 2009, Utility of Fibroscan in the evaluation of liver fibrosis, Gastroenterol Hepatol, 32, 415, 10.1016/j.gastrohep.2009.01.178 Bruno, 2017, Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response, Liver Int, 37, 1526, 10.1111/liv.13452 Vespaisani-Gentilucci, 2014, Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis, World J Gastroenterol, 20, 2825, 10.3748/wjg.v20.i11.2825 Negro, 2009, Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data, Liver Int, 29, 26, 10.1111/j.1478-3231.2008.01950.x Moucari, 2008, Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis, Gastroenterology, 134, 416, 10.1053/j.gastro.2007.11.010 2015, EASL recommendations on treatment of hepatitis C 2015, J Hepatol, 63, 199, 10.1016/j.jhep.2015.03.025 Lucidarme, 2009, Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C, Hepatology, 49, 1083, 10.1002/hep.22748 Arena, 2013, Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution, Hepatology, 58, 65, 10.1002/hep.26343 Castéra, 2005, Prospective comparison of transient elastography, Fibrotest APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C, Gastroenterology, 128, 343, 10.1053/j.gastro.2004.11.018 Lin, 2011, Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis, Hepatology, 53, 726, 10.1002/hep.24105 Vallet-Pichard, 2007, FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest, Hepatology, 46, 32, 10.1002/hep.21669 World Health Organization, 1999 World Health Organization (WHO), 2006 Bachofner, 2017, Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 and aspartate aminotransferase-platelet ratio index, Liver Int, 37, 369, 10.1111/liv.13256 Arena, 2008, Acute viral hepatitis increases liver stiffness values measured by transient elastography, Hepatology, 47, 380, 10.1002/hep.22007 Mauro, 2018, Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C, Hepatology, 67, 1683, 10.1002/hep.29557 Felmlee, 2013, Hepatitis C virus, cholesterol and lipoproteins-impact for the viral cycle and pathogenesis of liver disease, Viruses, 5, 1292, 10.3390/v5051292 Juanbeltz, 2017, Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions, Postgrad Med, 129, 476, 10.1080/00325481.2017.1311197 Hashimoto, 2016, Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment, PLos ONE, 11, e0163644, 10.1371/journal.pone.0163644 El Sagheer, 2018, Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs, Libyan J Med, 13, 1435124, 10.1080/19932820.2018.1435124 Pockros, 2017, Degree of liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with direct acting antivirals is overestimated but confirmed by liver biopsy, J Hepatol, 66, S108, 10.1016/S0168-8278(17)30475-0 Morales, 2016, Hepatitis C eradication with sofosbuvir leads to significant metabolic changes, World J Hepatol, 8, 1557, 10.4254/wjh.v8.i35.1557